Company name
Inossia AB

When was the company founded?
2013

Do you have any academic affiliations or collaborations?
Yes. Inossia AB is a spin-off company from Uppsala University. Professor Cecilia Persson is a co-founder and board member. The company continues to conduct research at Uppsala University, particularly within the Department of Materials Science and Engineering.

Describe your company
Inossia AB is a Swedish MedTech company originating from academic research at Uppsala University. The company was founded to address unmet needs in the treatment of osteoporotic spinal fractures and developed the Inossia® Cement Softener, designed for use with existing PMMA bone cements.
Inossia’s vision is to become the go-to solution for vertebral fractures by improving outcomes for patients with ageing spines through clinically validated, regulator-ready innovation. The company combines expertise in biomaterials research, medical device development, clinical studies and regulatory affairs, supported by an experienced founding team and a growing network of clinicians and industrial partners.

Describe your product/solution
The Inossia® Cement Softener (ICS) is added to injectable PMMA bone cement intended for stabilisation of vertebral compression fractures in osteoporotic patients. When ICS is incorporated into PMMA bone cement, the elastic modulus of the cement is reduced by more than 50%.

This modification aligns the mechanical properties of the cement more closely with the surrounding bone. By reducing stiffness mismatch, the treated vertebral segment achieves a more natural physiological load transfer profile. Load is distributed more evenly within the augmented vertebra and across adjacent levels, while preserving the established handling characteristics, fixation strength and clinical benefits of conventional PMMA cement.

What problem are you addressing?
Refractures following surgical treatment remain a major clinical challenge and represent a significant and growing burden worldwide. Osteoporotic vertebral compression fractures affect millions of elderly patients every year and are associated with pain, reduced mobility, increased morbidity and mortality.

Previous studies have reported refracture rates of up to 40% following vertebroplasty or kyphoplasty, which are current standard treatments. The Inossia Cement Softener has the potential to improve treatment outcomes by introducing a softer cement formulation that better matches the stiffness and strength of osteoporotic bone. This may improve load distribution and reduce the risk of subsequent fractures.

What impact does your solution create?
The Inossia Cement Softener has the potential to reduce refracture rates compared to currently available bone cements, improving outcomes for patients while reducing healthcare burden.

The solution is designed for ease of use. The softener is supplied in a separate vial within the cement package and mixed with the cement liquid in the operating room prior to surgery. Cement handling and injection procedures remain the same as with existing bone cements, meaning healthcare professionals do not need to learn a new surgical technique.

The addition of the softener also lowers the polymerisation temperature during hardening, reducing the risk of thermal necrosis. The lower hardening temperature extends working time and makes the material less sensitive to environmental temperature changes, improving injection safety and reducing the risk of surgical errors.
ICS is compatible with all PMMA-based bone cements currently available on the market, enabling strong scalability through partnerships, co-development projects and out-licensing opportunities with both local and global market players.
The technology also has broader application potential in areas such as vertebral fractures, degenerative disc disease and screw augmentation.

What stage of commercialisation are you currently in?
Inossia is currently in the clinical validation stage. The company has applied for CE marking and plans to apply for FDA approval in the near future.

What are you currently seeking to take the next step?
Inossia is currently seeking expert support to advance commercialisation, particularly within go-to-market strategy and legal contract and licensing structures.

This includes refining market positioning, identifying priority customer segments and defining a scalable market-entry strategy to transition from pilot activities to sustainable commercial growth. The company is also seeking guidance related to customer agreements, licensing models, intellectual property protection and partnership structures.

What market potential do you see for your solution?
Inossia’s business model, based on sales of ICS through established partners, creates strong scalability potential. Following regulatory approval, the product is intended to be distributed through partners’ existing commercial networks.
The initial market focus is vertebral compression fractures, followed by degenerative disc disease. ICS is chemically compatible with existing PMMA bone cements, which represent approximately 90% of the market.

For vertebral fracture treatment alone, around 400,000 procedures are performed annually across the U.S. and EU5 markets. Inossia estimates an initial market opportunity of approximately USD 300–600 million across these regions, with significant future expansion potential.
Degenerative disc disease remains in the preclinical pipeline and represents a major future opportunity, particularly for osteoporotic patients where few targeted solutions currently exist. The estimated addressable market potential is approximately USD 600 million to USD 1.8 billion.
The company is also exploring expansion into Asian markets in the coming years, creating additional international growth opportunities.

Website:
https://www.inossia.com/

Contact:

Salim Ghandour
Product Developer and Communications Manager
salim.ghandour@inossia.com

Download: https://medtech4health.se/wp-content/uploads/2026/05/Inossia-Series-A-Teaser-Deck_UIC.pdf